File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Prognostic significance and phenotypic manifestations of MYC/BCL2 protein expression in diffuse large B-cell lymphoma (DLBCL) with extranodal organ involvement: a report of the International DLBCL Rituximab-CHOP Consortium Program Study

TitlePrognostic significance and phenotypic manifestations of MYC/BCL2 protein expression in diffuse large B-cell lymphoma (DLBCL) with extranodal organ involvement: a report of the International DLBCL Rituximab-CHOP Consortium Program Study
Authors
Issue Date2012
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
Citation
The 54th Annual Meeting and Exposition of the American Society of Hematology (ASH 2012), Atlanta, GA., 8-11 December 2012. In Blood, 2012, v. 120 n. 21, abstract 544 How to Cite?
AbstractBACKGROUND: In DLBCL, multiple extranodal sites of involvement and MYC/BCL2 translocations (double hit lymphoma) are associated with a poor clinical outcome. The association between the pattern of extranodal involvement and MYC and BCL2 protein expression, as well as the prognostic significance of expression, are unknown. METHODS: We analyzed the clinical data of 487 DLBCL patients treated with R-CHOP. Immunohistochemical (IHC) studies were performed on paraffin-embedded tissue samples for MYC and BCL2. A double-hit score (DHS) of 0, 1, or 2 was assigned to all patients based on protein expression of MYC and BCL2. Those with both MYC and BCL2 expression were DHS 2, with MYC or BCL2 was DHS 1, and neither was DHS 0. Cell-of-origin classification was achieved by combining gene expression profiling (GEP) and IHC data with GEP as the gold standard. Patient characteristics were compared using Fisher's exact test. Survival analyses were performed using Kaplan-Meier curves and compared using log-rank test. The Cox proportional regression model was used for mult…
DescriptionOpen Access Journal
This journal issue is proceedings of ASH Conference 2012
Oral Sessions - 622. Non-Hodgkin Lymphoma - Biology, excluding Therapy: MYC And Others, The Usual Suspects
Persistent Identifierhttp://hdl.handle.net/10722/181799
ISSN
2015 Impact Factor: 11.841
2015 SCImago Journal Rankings: 6.395

 

DC FieldValueLanguage
dc.contributor.authorMadadi, Aen_US
dc.contributor.authorRaghavendra, Men_US
dc.contributor.authorHu, Sen_US
dc.contributor.authorXu-Monette, ZYen_US
dc.contributor.authorVisco, Cen_US
dc.contributor.authorTzankov, Aen_US
dc.contributor.authorMontes-Moreno, Sen_US
dc.contributor.authorDybkaer, Ken_US
dc.contributor.authorChiu, Aen_US
dc.contributor.authorOrazi, Aen_US
dc.contributor.authorZu, Yen_US
dc.contributor.authorBhagat, Gen_US
dc.contributor.authorDunphy, CHen_US
dc.contributor.authorHsi, EDen_US
dc.contributor.authorZhao, FXen_US
dc.contributor.authorChoi, WWLen_US
dc.contributor.authorZhao, Xen_US
dc.contributor.authorVan Krieken, JHJMen_US
dc.contributor.authorHuh, Jen_US
dc.contributor.authorHuang, Qen_US
dc.contributor.authorAi, Wen_US
dc.contributor.authorPonzoni, Men_US
dc.contributor.authorFerreri, AJMen_US
dc.contributor.authorZhou, Fen_US
dc.contributor.authorWinter, JNen_US
dc.contributor.authorPiris, Men_US
dc.contributor.authorMøller, MBen_US
dc.contributor.authorMedeiros, LJen_US
dc.contributor.authorGo, RSen_US
dc.contributor.authorYoung, KHen_US
dc.date.accessioned2013-03-19T03:58:30Z-
dc.date.available2013-03-19T03:58:30Z-
dc.date.issued2012en_US
dc.identifier.citationThe 54th Annual Meeting and Exposition of the American Society of Hematology (ASH 2012), Atlanta, GA., 8-11 December 2012. In Blood, 2012, v. 120 n. 21, abstract 544en_US
dc.identifier.issn0006-4971-
dc.identifier.urihttp://hdl.handle.net/10722/181799-
dc.descriptionOpen Access Journal-
dc.descriptionThis journal issue is proceedings of ASH Conference 2012-
dc.descriptionOral Sessions - 622. Non-Hodgkin Lymphoma - Biology, excluding Therapy: MYC And Others, The Usual Suspects-
dc.description.abstractBACKGROUND: In DLBCL, multiple extranodal sites of involvement and MYC/BCL2 translocations (double hit lymphoma) are associated with a poor clinical outcome. The association between the pattern of extranodal involvement and MYC and BCL2 protein expression, as well as the prognostic significance of expression, are unknown. METHODS: We analyzed the clinical data of 487 DLBCL patients treated with R-CHOP. Immunohistochemical (IHC) studies were performed on paraffin-embedded tissue samples for MYC and BCL2. A double-hit score (DHS) of 0, 1, or 2 was assigned to all patients based on protein expression of MYC and BCL2. Those with both MYC and BCL2 expression were DHS 2, with MYC or BCL2 was DHS 1, and neither was DHS 0. Cell-of-origin classification was achieved by combining gene expression profiling (GEP) and IHC data with GEP as the gold standard. Patient characteristics were compared using Fisher's exact test. Survival analyses were performed using Kaplan-Meier curves and compared using log-rank test. The Cox proportional regression model was used for mult…-
dc.languageengen_US
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/-
dc.relation.ispartofBlooden_US
dc.titlePrognostic significance and phenotypic manifestations of MYC/BCL2 protein expression in diffuse large B-cell lymphoma (DLBCL) with extranodal organ involvement: a report of the International DLBCL Rituximab-CHOP Consortium Program Studyen_US
dc.typeConference_Paperen_US
dc.identifier.emailChoi, WWL: choiwl@hkucc.hku.hken_US
dc.identifier.authorityChoi, WWL=rp00247en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros213554en_US
dc.identifier.volume120-
dc.identifier.issue21-
dc.publisher.placeUnited States-
dc.customcontrol.immutablesml 130326-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats